Cyteir Therapeutics, Inc. — Form D/A
Cyteir Therapeutics, Inc. of LEXINGTON, MA, a company, filed a Form D amendment with the SEC on 2018-05-16. The offering totals $35.0M, of which $5.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-05-16
- Form: D/A
- Accession: 0001662244-18-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $35.0M
- Amount sold: $5.8M
- Remaining: $29.2M
- Investors: 12
- Date of first sale: 2018-01-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-308831
Issuer
- Name: Cyteir Therapeutics, Inc.
- CIK: 0001662244
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 128 SPRING STREET, LEXINGTON, MA, 02421
- Phone: 857-285-4140
Officers, directors & promoters (23)
| Name | Role | Location |
|---|
| Bart Van Hooland | Director | Cambridge, MA |
| Ronald Goldstein | Executive Officer | Cambridge, MA |
| Kevin Mills | Director | Fremont, CA |
| Kevin Mills | Executive Officer | Fremont, CA |
| Janwillem Naesens | Director | San Francisco, CA |
| Joseph S Zakrzewski | Director | Denver, CO |
| Karen Hong | Director | Princeton, NJ |
| TIMOTHY S ROMBERGER | Director | LEXINGTON, MA |
| PAUL S SECRIST | Executive Officer | LEXINGTON, MA |
| ANDREW S GENGOS | Executive Officer | LEXINGTON, MA |
| SUSAN S MOLINEAUX | Director | LEXINGTON, MA |
| JEAN GEORGE | Director | LEXINGTON, MA |
| RACQUEL BRACKEN | Director | LEXINGTON, MA |
| MARKUS RENSCHLER | Director | LEXINGTON, MA |
| MARKUS RENSCHLER | Executive Officer | LEXINGTON, MA |
| TIMOTHY ROMBERGER | Director | LEXINGTON, MA |
| TIMOTHY ROMBERGER | Executive Officer | LEXINGTON, MA |
| Barry Mills | Director | Cambridge, MA |
| Donald Corcoran | Director | Cambridge, MA |
| Donald Corcoran | Executive Officer | Cambridge, MA |
| William B Asher, Jr. | Executive Officer | Cambridge, MA |
| Timothy B Romberger | Director | Cambridge, MA |
| Barry B Mills | Director | Cambridge, MA |
Other filings by this issuer (5)
More